Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-04-15
2008-04-15
Carlson, Karen Cochrane (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
07358224
ABSTRACT:
The invention relates to the use of an agent that promotes class III SLRP activity in the manufacture of a medicament for the inhibition of blood vessel formation. In addition the invention relates to the use of an agent that promotes class III SLRP activity in the manufacture of a medicament for the prevention and/or treatment of conditions characterised by excessive activity and/or migration of monocytes and/or macrophages. Suitable agents may include class III SLRPs such as opticin. Methods of treatment using agents able to promote class III SLRP activity are also provided.
REFERENCES:
patent: 6413931 (2002-07-01), Yang et al.
patent: 2002/0115589 (2002-08-01), Nixon et al.
patent: 2003/0148351 (2003-08-01), Mayne et al.
patent: 4445630 (1996-06-01), None
patent: WO 97/15330 (1997-05-01), None
patent: WO 98/13071 (1998-04-01), None
patent: WO 98/24466 (1998-06-01), None
patent: WO 01/19386 (2001-03-01), None
Canfield, A.E. et al., “Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells,” J. Cell Sci. (1995) 108:797-809.
Friedman, J.S. et al., “Protein localization in the human eye and genetic screen of opticin,” Human Mol. Genet. (2002) 11(11):1333-1342.
Le Goff et al., “Characterization of opticin and evidence of stable dimerisation in solution,” J. Biol. Chem. (2003) 278:45280-45287.
Pellegrini, B. et al., “Cloning and characterization of opticin cDNA: evaluation as a candidate for canine oculo-skeletal dysplasia,” Gene (2002) 282:121-131.
Slevin, M. et al., “Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses,” J. Biol. Chem. (2002) 277:41046-41059.
Stander, M. et al., “Transforming growth factor-beta and p-21 : multiple molecular targets of decorin-mediated suppression of neoplastic growth,” Cell Tiss. Res. (1999) 296(2):221-227.
Tasheva, E.S., “Analysis of the promoter region of human mimecan gene,” Biochimica et Biophysica Acta (2002) 1575(1-3):123-129.
Tralhao, J.G. et al., “In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer,” The FASEB Journal (Jan. 2003) 17(3):464-466.
Vuillermoz, B. et al., “The small leucine-rich proteoglycan lumican inhibits melanoma progression,” Exp. Cell Res. (2004) 296(2):294-306.
Carlson Karen Cochrane
Michael & Best & Friedrich LLP
The University of Manchester
LandOfFree
Class III SLRP agonists for the reduction of blood vessel... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Class III SLRP agonists for the reduction of blood vessel..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Class III SLRP agonists for the reduction of blood vessel... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2748285